Efficacy of bisphosphonates against osteoporosis in adult men: a meta-analysis of randomized controlled trials

[1]  E. M. Lewiecki,et al.  Clinician’s Guide to Prevention and Treatment of Osteoporosis , 2014, Osteoporosis International.

[2]  P. Ebeling,et al.  Treatment of osteoporosis in men with bisphosphonates: rationale and latest evidence , 2013, Therapeutic advances in musculoskeletal disease.

[3]  P. Ebeling.  Osteoporosis in men , 2013, Current opinion in rheumatology.

[4]  J. Reginster,et al.  Fracture risk and zoledronic acid therapy in men with osteoporosis. , 2012, The New England journal of medicine.

[5]  Wei Wang,et al.  Is There Really No Benefit of Vertebroplasty for Osteoporotic Vertebral Fractures? A Meta-analysis , 2012, Clinical orthopaedics and related research.

[6]  D. Boluki.  Operative Behandlung osteoporotischer Wirbelkörperfrakturen , 2011, Zeitschrift für Rheumatologie.

[7]  Jacques P. Brown,et al.  Efficacy and safety of a once‐yearly i.v. Infusion of zoledronic acid 5 mg versus a once‐weekly 70‐mg oral alendronate in the treatment of male osteoporosis: A randomized, multicenter, double‐blind, active‐controlled study , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[8]  K. Tsai,et al.  The effects of weekly alendronate therapy in Taiwanese males with osteoporosis , 2010, Journal of Bone and Mineral Metabolism.

[9]  E. Orwoll,et al.  Efficacy and safety of monthly ibandronate in men with low bone density. , 2010, Bone.

[10]  J. Iwamoto,et al.  Comparison of the Effects of Alendronate and Alfacalcidol on Hip Bone Mineral Density and Bone Turnover in Japanese Men Having Osteoporosis or Osteopenia with Clinical Risk Factors for Fractures , 2009, Yonsei medical journal.

[11]  Claire Bombardier,et al.  2009 Updated Method Guidelines for Systematic Reviews in the Cochrane Back Review Group , 2009, Spine.

[12]  S. Boonen,et al.  Once‐Weekly Risedronate in Men With Osteoporosis: Results of a 2‐Year, Placebo‐Controlled, Double‐Blind, Multicenter Study , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[13]  S. Boonen,et al.  Zoledronic acid and clinical fractures and mortality after hip fracture. , 2007, The New England journal of medicine.

[14]  S. Cummings,et al.  Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. , 2007, The New England journal of medicine.

[15]  P. Farahmand,et al.  Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study , 2006, Rheumatology International.

[16]  M. Drezner,et al.  Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study , 2005, Annals of the rheumatic diseases.

[17]  A. Gafni,et al.  Does Alendronate reduce the risk of fracture in men? A meta-analysis incorporating prior knowledge of anti-fracture efficacy in women , 2005, BMC musculoskeletal disorders.

[18]  G. Guyatt,et al.  Systems for grading the quality of evidence and the strength of recommendations II: Pilot study of a new system , 2005, BMC health services research.

[19]  J. Ringe,et al.  Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study , 2004, Rheumatology International.

[20]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[21]  S. Gonnelli,et al.  Alendronate Treatment in Men With Primary Osteoporosis: A Three-Year Longitudinal Study , 2003, Calcified Tissue International.

[22]  L. Melton,et al.  The Prevalence of Osteoporosis: Gender and Racial Comparison , 2001, Calcified Tissue International.

[23]  P Geusens,et al.  Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. , 2001, The New England journal of medicine.

[24]  E. Orwoll,et al.  Alendronate for the treatment of osteoporosis in men. , 2000, The New England journal of medicine.

[25]  J. Eisman,et al.  Mortality after all major types of osteoporotic fracture in men and women: an observational study , 1999, The Lancet.

[26]  H. Pols,et al.  Evidence for Involvement of 17β‐Estradiol in Intestinal Calcium Absorption Independent of 1,25‐Dihydroxyvitamin D3 Level in the Rat , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[27]  A. LaCroix,et al.  Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. , 1998, JAMA.

[28]  Jacques P. Brown,et al.  Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis , 1998 .

[29]  A. Parfitt,et al.  Relationship between bone formation rate and osteoblast surface on different subdivisions of the endosteal envelope in aging & osteoporosis. , 1992, Bone.

[30]  S. Boonen,et al.  Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: a systematic review. , 2014, Bone.

[31]  H. Kamel.  Male Osteoporosis , 2005, Drugs & aging.

[32]  M. Hooper,et al.  Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis , 2000, Osteoporosis International.